Annexon has initiated patient dosing in a phase 2 trial investigating ANX007 for the treatment of geographic atrophy, according to a press release.
The efficacy and safety of anti-C1q therapy ANX007, an investigational monoclonal antibody antigen-binding fragment, will be studied in the randomized, multicenter, double-masked ARCHER trial. The reduction of areas of geographic atrophy will be evaluated by fundus autofluorescence, with the study including monthly and bimonthly dosing schedules.
“This program harnesses our targeted anti-C1q approach, fully inhibiting the classical complement
Uncategorized